Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $894.97M
• Dividend Yield: N/A
• Average Volume (3M): 1.45M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: -30.56%
• EPS Growth: 48.79%
• Country: US
• Employees: 570
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 145,022,750
• 10 Day Avg. Volume: 1,385,104
• 30 Day Avg. Volume: 1,446,570
• PEG Ratio: -0.31
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 2.90
• P/FCF Ratio: -33.87
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 3.78
• Enterprise Value/Gross Profit: 18.10
• Enterprise Value/Ebitda: -5.76
• 1Y Price Target: $4.00
• Price Target Upside: 23.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $3.50 ▲(7.69% Upside)

Maravai Lifesciences Holdings is currently facing significant financial challenges, with declining revenue and profitability being the most critical factors. Despite positive technical indicators suggesting short-term bullish momentum, the negative valuation metrics and absence of dividends weigh heavily on the stock's attractiveness. The company's strategic initiatives and cost-cutting measures offer some hope for future improvement, but the financial outlook remains pressured.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai Lifesciences Holdings (MRVI) is a leading provider of life sciences tools and services, focused on enabling the development of new therapies and the advancement of scientific research. The company operates primarily in three sectors: nucleic acid production, protein detection, and cell line development. Its core products include custom nucleic acids, detection reagents, and cell line development services, which are critical for applications in genomics, diagnostics, and biopharmaceutical manufacturing.

How the Company Makes Money

Maravai Lifesciences generates revenue through multiple streams, primarily by providing high-quality nucleic acid products and services to biotechnology and pharmaceutical companies, academic institutions, and contract research organizations. Key revenue streams include sales of custom oligonucleotides, RNA production, and reagents for molecular biology applications. The company also benefits from partnerships with major players in the biopharmaceutical industry, enhancing its market position and driving sales growth. Furthermore, the increasing demand for mRNA-based therapeutics and vaccines, particularly highlighted during the COVID-19 pandemic, has contributed significantly to Maravai's earnings, as its products are pivotal in the development and manufacturing of these innovative therapies.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.25
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Neutral. The current price of 3.25 is below the 20-day moving average (MA) of 3.58, below the 50-day MA of 3.41, and above the 200-day MA of 2.65, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 42.42 is Neutral, neither overbought nor oversold. The STOCH value of 10.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
RLAY	59 Neutral	$1.49B	-4.75	-41.14%	―	-16.50%	33.02%
IMTX	56 Neutral	$1.39B	-9.34	-29.01%	―	-27.61%	-69.49%
MRVI	49 Neutral	$894.97M	-3.90	-41.06%	―	-30.56%	48.79%
KURA	47 Neutral	$980.69M	-4.35	-65.10%	―	―	-5.18%
GHRS	45 Neutral	$807.62M	-17.43	-17.86%	―	―	8.16%
IVA	44 Neutral	$851.21M	-1.07	―	―	-12.52%	-82.84%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Streamlines Board with Recent Resignations

On October 21, 2025, Maravai LifeSciences Holdings, Inc. announced the voluntary resignation of three board members—Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD—as part of its strategy to streamline its Board of Directors and cut administrative costs. Consequently, the board’s size was reduced from eleven to eight members, effective October 27, 2025. The resignations were not due to any disagreements with the company’s management or policies. Following these changes, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and a member of the Audit Committee, while Gregory T. Lucier joined the Nominating, Governance and Risk Committee. The company also accelerated the vesting of all unvested restricted stock unit awards for the departing directors.